Diversified Healthcare Trust (DHC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects positive financial performance with significant improvements in NOI margins and leverage reduction. The strategic focus on operational performance and disciplined capital spending is promising. While the Q&A revealed some uncertainties, such as unclear timelines for reopening wings and acquisition strategies, the overall outlook remains optimistic. The positive elements, including strong occupancy and pricing momentum, outweigh the minor concerns, supporting a positive sentiment.
Key Financial Performance
Full Year Consolidated NOI Growth 31.3% year-over-year increase, driven by capital markets activity, asset sales, and operational improvements.
SHOP NOI (Q4) $38.3 million, a 27.6% year-over-year increase, attributed to execution on initiatives and strengthened financial position.
Total Revenue (Q4) $379.6 million, no specific year-over-year change mentioned.
Adjusted EBITDAre (Q4) $72.4 million, no specific year-over-year change mentioned.
Normalized FFO (Q4) $21.8 million or $0.09 per share, no specific year-over-year change mentioned.
SHOP NOI (Full Year) $139.3 million, towards the high end of guidance, driven by a 90 basis point increase in same-property occupancy to 82.4% and a 5.8% increase in average monthly rate.
Same-Property SHOP NOI Margins Improved by 230 basis points year-over-year, driven by revenue growth.
Medical Office and Life Science Portfolio NOI (Q4) Same-property cash basis NOI increased 3.8% year-over-year, with margins improving 100 basis points to 59.6%.
Leverage Reduction Net debt to adjusted EBITDA reduced from 11.2x at year-end 2024 to 8.1x at the end of 2025, achieved through asset sales and debt repayment.
Same-Property Cash Basis NOI (Q4) $70.4 million, a 15.4% year-over-year increase, driven by pricing momentum and occupancy growth.
Capital Expenditures (Full Year) $146 million, a 23% reduction compared to 2024, reflecting disciplined capital spending.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SHOP NOI: Improved 27.6% year-over-year to $38.3 million in Q4 2025, with full-year SHOP NOI at $139.3 million, driven by increased occupancy and average monthly rates.
Advanced CRM platforms: Rolled out to improve lead-to-move-in conversion rates.
Repositioning underutilized areas: Plans to renovate and reopen areas like closed skilled nursing wings, potentially adding 500 SHOP units with mid-teens ROI.
Leasing in Medical Office and Life Science portfolio: Completed 81,000 square feet of leasing in Q4 2025 at rents 7.9% above prior levels, with consolidated occupancy increasing to 91.2%.
Leasing pipeline: Active pipeline of 1 million square feet with average lease terms of 6.9 years and GAAP rent spreads averaging over 10%.
Capital markets activity: Completed over $1.4 billion in 2025, including financing, asset sales, and establishing a $150 million undrawn credit facility.
Debt reduction: Reduced net debt to adjusted EBITDA from 11.2x to 8.1x in 2025, with no maturities until 2028.
Disposition program: Sold 69 properties for $605 million in 2025, with proceeds used to repay debt and reduce leverage.
Focus on SHOP portfolio: Targeting higher lead-to-move-in conversion, dynamic pricing strategies, and differentiated care levels to meet market demand.
Deleveraging efforts: Aiming for leverage levels of 6.5x to 7.5x, with a focus on reducing debt and improving financial stability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Transition of 116 SHOP communities to new operators: The transition of 116 SHOP communities to seven different operators, while completed, introduces operational risks due to the need for alignment and execution of property-specific business plans with new operators.
Leasing pipeline and tenant retention: 10.1% of annualized revenue in the Medical Office and Life Science portfolio is scheduled to expire through 2026, with 3.9% expected to vacate, posing risks to revenue stability and occupancy rates.
Debt and leverage: Although leverage has been reduced, the company still has a net debt to adjusted EBITDAre of 8.1x, which is above the targeted range of 6.5x to 7.5x, indicating ongoing financial risk.
Capital expenditure reductions: The planned reduction in capital expenditures for 2026 may limit the ability to address unforeseen maintenance or investment needs, potentially impacting operational efficiency.
Dependence on SHOP NOI growth: The company’s financial improvement heavily relies on SHOP NOI growth, which is subject to market conditions, occupancy rates, and operational execution.
Disposition of properties: The sale of 13 SHOP communities expected to close in March for $23 million may reduce revenue streams, as these properties contributed losses in the short term but could have potential long-term value.
Economic and market conditions: The company’s performance is tied to favorable market conditions, including demand for senior housing and muted new supply, which are subject to change and could impact growth projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SHOP NOI: Expected to be between $175 million to $185 million for 2026, reflecting strong improvements in the SHOP segment.
Medical Office and Life Science NOI: Projected to range from $94 million to $98 million in 2026, with a decline attributed to the sale of 31 properties that contributed $12.3 million of NOI in 2025.
Triple Net Lease Portfolio NOI: Anticipated to be between $28 million to $30 million in 2026, with a slight decline due to the sale of 18 triple-net leased senior living communities in February 2025.
Adjusted EBITDAre: Forecasted to be between $290 million and $305 million for 2026.
Normalized FFO: Expected to range from $0.52 to $0.58 per share in 2026.
Recurring Capital Expenditures: Projected to range from $100 million to $115 million in 2026, representing an over 18% decrease at the midpoint compared to 2025.
SHOP Recurring Capital Expenditures: Expected to be $80 million to $90 million, including approximately $10 million of refresh ROI capital.
Medical Office and Life Science Recurring Capital Expenditures: Anticipated to range from $20 million to $25 million in 2026.
Leverage Reduction: Targeted leverage levels of 6.5x to 7.5x, with net debt to adjusted EBITDAre expected to improve to at or above 2x by year-end 2026.
SHOP Unit Expansion: Plans to add approximately 500 SHOP units through the repositioning of underutilized areas, with potential to deliver an unlevered mid-teens ROI.
Leasing Pipeline: Active pipeline totaling 1 million square feet, with average lease terms of 6.9 years and GAAP rent spreads averaging more than 10%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the go-forward strategy from here? Can you provide some color on the opportunities to reopen the wings that you talked about at existing communities?
A:The main strategy is to unlock value through operational performance. There are about 15 locations identified for reopening wings, potentially adding close to 500 units with mid-teens ROI. Costs are estimated at $125,000 to $175,000 per unit, but this will occur over time and not all in 2026.
Q:Will external investments still focus on renovations, or is there consideration for acquisitions?
A:Renovations offer a better risk-adjusted return, especially for introducing new care options like memory care. Acquisitions are not a current focus but may be considered in the future depending on progress and capital recycling.
Q:What drove the 4Q margin improvement? Was it due to transition disruptions dissipating or core operational gains?
A:It was a combination of both. Transition disruptions were more material in Q3, and as operators adjusted cost structures, there was a benefit in Q4 that is expected to continue into 2026.
Q:Were there any specific costs in 4Q related to transitions?
A:There was a small impact in Q4, but it was not material, making it a decent run rate.
Q:Can you discuss January and February trends, including any impact from the flu season and rent escalators?
A:January trends were promising and aligned with expectations. Rent escalators ranged from 4% to 6%, primarily on legacy Aleris properties. The flu season had no outsized impact on the portfolio.
Q:Should NOI growth implied in guidance be back half of the year weighted due to operator transitions?
A:Yes, growth will be back half-weighted, with occupancy improvements expected in Q2 and Q3. Rate increases will contribute early in the year, while other benefits will take time to materialize.
Q:Is the 300 basis points of occupancy growth in guidance compared to 4Q end occupancy or average occupancy over 2025?
A:It is compared to the full-year average occupancy over 2025.
Q:What drove the sequential decline in rental revenue in 4Q compared to 3Q?
A:The decline was due to asset sales and tempered operations during transitions, but this noise is now behind, starting with a clean slate in 2026.
Q:What margin expansion is implied with RevPOR growth in 2026?
A:The flow-through is expected to result in a couple of hundred basis points of margin improvement on a same-store basis.
Q:What are the prospects for renewing or releasing leases expiring in 2026 for MOB and Life Science assets?
A:Two primary tenants are vacating in 2026. The Minnesota building will likely transition to a multi-tenant setup, while the Fremont building has strong prospects for re-leasing due to its location in a robust R&D market.
Q:Will dispositions be more focused on MOB Life Science assets given SHOP transitions?
A:There is slightly more opportunity for dispositions in MOB Life Science assets, as many SHOP assets were sold in 2025. However, no specific sales are currently planned.
Q:What implications does the significant momentum have on the dividend?
A:The focus for 2026 is on operational improvements. While growth in NOI, normalized FFO, and adjusted EBITDA is expected, there are no immediate plans to address the dividend.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the cost estimates for reopening wings, stating that the figures are still premature. Additionally, they did not commit to a clear timeline or strategy for acquisitions, only mentioning it as a potential future consideration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CRM platform
GA expense
Medical Office
NOI basis
NOI interest
NOI lead
NOI position
NOI reduction
Office Life
REIT share
RMR incentive
SHOP capital
SHOP project
SHOP unit
Science portfolio
accomplishment investment
activity financing
acuity need
addition opportunity
agreement property
amount capital
appreciation shareholder
area
capital expenditure
capital market
demand
housing
increase property
industry
leverage
momentum
operator
portfolio NOI
program
property SHOP
share price
shareholder return
spend
transition
DHC Transcript
Diversified Healthcare Trust (DHC) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reflects positive financial performance with significant improvements in NOI margins and leverage reduction. The strategic focus on operational performance and disciplined capital spending is promising. While the Q&A revealed some uncertainties, such as unclear timelines for reopening wings and acquisition strategies, the overall outlook remains optimistic. The positive elements, including strong occupancy and pricing momentum, outweigh the minor concerns, supporting a positive sentiment.
Diversified Healthcare Trust (DHC) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights positive financial performance with increased revenues, NOI, and occupancy across various segments. Despite temporary labor cost increases, the company maintains strong guidance and expects favorable transitions. The Q&A section reveals management's confidence in achieving targets and mitigating risks. The increase in SHOP NOI guidance and active disposition pipeline further support a positive outlook. However, the lack of specific details on potential revenue disruptions and disposition delays warrants caution. Overall, the sentiment leans towards positive due to strong financial metrics and optimistic guidance.
Diversified Healthcare Trust (DHC) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong financial performance with a 3% revenue increase and a significant 172% FFO growth, driven by operational improvements. Despite high interest rates on new financing, the company's asset sales and debt management strategies are positive. The Q&A reveals strategic asset dispositions and gradual occupancy growth, with no major negative trends. The reaffirmed guidance and improved debt metrics indicate stability. Overall, the sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
Earnings call transcript: Diversified Healthcare Trust beats Q1 2025 earnings forecast
Unknown5-6
The earnings call presents a mixed sentiment. Financial performance is strong with revenue and EBITDA growth, but guidance is weak, particularly in SHOP results. The market strategy shows proactive debt management and asset sales, but reduced CapEx limits growth. Shareholder returns focus on deleveraging, with uncertain future dividends. Q&A reveals some positive occupancy trends but also highlights uncertainties in guidance and future dividends. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement.
DHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
